Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||ALT-803 + CIML-NK cells + Ipilimumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ALT-803||N-803|N803|Nogapendekin alfa|ALT803||ALT-803 (Nogapendekin alfa) is a fusion protein consisting a mutant IL-15 and a soluble IL-15Ra Fc, which activates and converts memory CD8+ T cells to effector immune cells with antitumor activity (PMID: 24404427, PMID: 31338557).|
|CIML-NK cells||CIML-NK cells are allogeneic cytokine-induced memory-like natural killer (CIML-NK) cells, which potentially enhance cytotoxic anti-tumor immune response (NCI Drug Dictionary).|
|Ipilimumab||Yervoy||BMS-734016||CTLA4 Antibody 22 Immune Checkpoint Inhibitor 147||Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (including patients 12 years or older), hepatocellular carcinoma previously treated with Nexavar (sorafenib), in combination with Opdivo (nivolumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Opdivo (nivolumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04290546||Phase I||ALT-803 + CIML-NK cells + Ipilimumab ALT-803 + CIML-NK cells||CIML NK Cell in Head & Neck Cancer||Recruiting||USA||0|